171 related articles for article (PubMed ID: 30427809)
1. Drug-drug Interactions in Psychiatric Practice, Part 1: Reasons, Importance, and Strategies to Avoid and Recognize Them.
Preskorn SH
J Psychiatr Pract; 2018 Jul; 24(4):261-268. PubMed ID: 30427809
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants.
Preskorn SH
J Psychiatr Pract; 2020 Jan; 26(1):46-51. PubMed ID: 31913969
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs.
Preskorn SH
J Psychiatr Pract; 2018 Sep; 24(5):341-347. PubMed ID: 30427821
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
Preskorn SH
J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
[TBL] [Abstract][Full Text] [Related]
5. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 5: Major Types of Pharmacodynamic DDIs Based on Mechanism of Action (With Updated Neuroscience-based Nomenclature).
Preskorn SH; Germann A
J Psychiatr Pract; 2019 May; 25(3):206-211. PubMed ID: 31083033
[TBL] [Abstract][Full Text] [Related]
6. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations.
Preskorn SH
J Psychiatr Pract; 2019 Jul; 25(4):290-297. PubMed ID: 31291209
[TBL] [Abstract][Full Text] [Related]
7. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics.
Preskorn SH
J Psychiatr Pract; 2019 Nov; 25(6):461-465. PubMed ID: 31821222
[TBL] [Abstract][Full Text] [Related]
8. Potential drug-drug interactions and polypharmacy in institutionalized elderly patients in a public hospital in Brazil.
Castilho ECD; Reis AMM; Borges TL; Siqueira LDC; Miasso AI
J Psychiatr Ment Health Nurs; 2018 Feb; 25(1):3-13. PubMed ID: 28892271
[TBL] [Abstract][Full Text] [Related]
9. Drug-drug Interactions in Psychiatric Practice, Part 4: Classification of Neuropsychiatric Medications Based on Their Principal Mechanisms of Action (With Updated Neuroscience-based Nomenclature).
Preskorn SH; Germann A
J Psychiatr Pract; 2019 Mar; 25(2):118-127. PubMed ID: 30849059
[TBL] [Abstract][Full Text] [Related]
10. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
11. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations.
Preskorn SH
J Psychiatr Pract; 2019 Jan; 25(1):34-40. PubMed ID: 30633730
[TBL] [Abstract][Full Text] [Related]
12. Adverse Events, Drug Interactions, and Treatment Adherence.
Limandri BJ
J Psychosoc Nurs Ment Health Serv; 2020 Feb; 58(2):9-13. PubMed ID: 32003860
[TBL] [Abstract][Full Text] [Related]
13. Managing Psychotropic Medications in Complex, Real-World Patients Using Comprehensive Therapeutic Drug Monitoring.
Sutherland JJ; Morrison RD; Daniels JS; Milne SB; Ryan TP
ACS Chem Neurosci; 2017 Aug; 8(8):1641-1644. PubMed ID: 28640591
[TBL] [Abstract][Full Text] [Related]
14. Consistency of psychotropic drug-drug interactions listed in drug monographs.
Liu X; Hatton RC; Zhu Y; Hincapie-Castillo JM; Bussing R; Barnicoat M; Winterstein AG
J Am Pharm Assoc (2003); 2017; 57(6):698-703.e2. PubMed ID: 28844584
[TBL] [Abstract][Full Text] [Related]
15. Off-Label Prescribing and Polypharmacy: Minimizing the Risks.
Leahy LG
J Psychosoc Nurs Ment Health Serv; 2017 Feb; 55(2):17-22. PubMed ID: 28218925
[TBL] [Abstract][Full Text] [Related]
16. Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?
Preskorn SH; Quadri S
J Psychiatr Pract; 2020 Nov; 26(6):485-492. PubMed ID: 33275385
[TBL] [Abstract][Full Text] [Related]
17. A framework to avoid irrational polypharmacy in psychiatry.
Zigman D; Blier P
J Psychopharmacol; 2012 Dec; 26(12):1507-11. PubMed ID: 22767374
[TBL] [Abstract][Full Text] [Related]
18. PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.
Davies SJ; Lennard MS; Ghahramani P; Pratt P; Robertson A; Potokar J
J Psychopharmacol; 2007 Mar; 21(2):153-60. PubMed ID: 17329294
[TBL] [Abstract][Full Text] [Related]
19. [Polypharmacy in psychiatric patients as an alternative to limited mental health resources].
de las Cuevas C; Sanz EJ; de la Fuente JA; Cueto M
Actas Esp Psiquiatr; 2005; 33(2):81-6. PubMed ID: 15768314
[TBL] [Abstract][Full Text] [Related]
20. Characterization of drug-drug interactions in patients whose substance intake was objectively identified by detection in urine.
Schrecker J; Puet B; Hild C; Schwope DM
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):973-978. PubMed ID: 30092669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
